Table 1.
Clinical baseline characteristics of the patients.
| Variables | |
|---|---|
| Number of patients, n | 9 |
| Men/women, n | 3/6 |
| Age, years | 71.3 (11.9) |
| BMI, kg/m2 | 26.0 (4.8) |
| Duration of diabetes, years | 12 [8–41] |
| HbA1c, % | 6.9 (0.8) |
| Serum potassium, mEq/L | 4.3 (0.4) |
| eGFR, mL/min/1.73m2 | 18.6 (3.2) |
| UPCR, g/gCr | 4.6 (3.5) |
| Systolic BP, mmHg | 130 (17.7) |
| TC, mg/dL | 194 (33.0) |
| TG, mg/dL | 165 [96–345] |
| HDL-C, mg/dL | 44 [73–75] |
| Medications | |
| Glinide, n (%) | 1 (11.1) |
| DPP4 inhibitor, n (%) | 3 (27.3) |
| SGLT2 inhibitor, n (%) | 6 (66.7) |
| Statin, n (%) | 1 (55.6) |
| EPA, n (%) | 1 (11.1) |
| ARB, n (%) | 1 (11.1) |
| ARNI, n (%) | 1 (11.1) |
| Ca-blocker, n (%) | 4 (44.4) |
| α-blocker, n (%) | 1 (11.1) |
| αβ-blocker, n (%) | 3 (27.3) |
| Thiazide, n (%) | 3 (27.3) |
| Loop diuretics, n (%) | 2 (22.2) |
BMI, body mass index; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; UPCR, urine protein-creatinine ratio; BP, blood pressure; TC, total cholesterol; TG, triglyceride, HDL-C, high-density lipoprotein cholesterol; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2; EPA, eicosapentaenoic acid; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; Ca, calcium.
Age, BMI, HbA1c, serum potassium, eGFR, UPCR, systolic BP, TC were expressed as mean±standard deviation. Duration of diabetes, TG, HDL-C were expressed as median.